Affinivax, PATH collaborate on pneumococcal disease vaccine candidate

Friday, February 13, 2015

Affinivax, a Cambridge, Mass.-based biotechnology company dedicated to developing novel vaccines, has entered into a collaboration with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate for Streptococcus pneumoniae (pneumococcus). The partnership includes funding from PATH to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance toward clinical testing.

[Read More]